Cyclooxygenase-2 polymorphisms and pancreatic cancersSusceptibility

Pancreas

Volumn 40, Issue 8, 2011, Pages 1289-1294

  Özhan, Gül ^a   Lochan, Rajiv ^b,c   Leathart, Julian B S ^c   Charnley, Richard ^b   Daly, Ann K ^c  

^a ISTANBUL UNIVERSITY   (Turkey)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

COX 2; pancreatic cancer; SNPs

Indexed keywords

CYCLOOXYGENASE 2;

AGED; CANCER PATIENT; CANCER SUSCEPTIBILITY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; ENZYME POLYMORPHISM; EUROPE; FEMALE; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING HABIT;

ADULT; AGED; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 80054860998     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31821fcc3b     Document Type: Conference Paper

References (43)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet. 1997;349:485-489.
3. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nature Gen. 2009;41(9):986-992.
4. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999;18:7908-7916.
5. Ristimaki A, Honkanen N, Jankala H, et al. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997;57:1276-1280.
6. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 1998;58:4997-5001.
7. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 1999;59:991-994.
8. Fujita T, Matsui M, Takaku K, et al. Size- and invasion-dependent increase in cyclooxygenase-2 levels in human colorectal carcinomas. Cancer Res. 1998;58:4823-4826.
9. Hwang D, Scollard D, Byrne J, et al. Expression of cyclooxygense-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 1998;90:455-460.
10. AkkNz H, Bayram S, Bekar A, et al. Functional polymorphisms of cyclooxygenase-2 gene and risk for hepatocellular carcinoma. Mol Cell Biochem. 2011;347(1-2):201-208.
11. Gangwar R, Mandhani A, Mittal RD. Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for urinary bladder cancer in North India. Surgery. 2011;149(1):126-134.
12. Kokawa A, Kondo H, Gotoda T, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer. 2001;91:333-338.
13. Molina MA, Sitja Arnau M, Lemoine MG, et al. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti inflammatory drugs. Cancer Res. 1999;59:4356-4362.
14. Martey CA, Pollock SJ, Turner CK, et al. Cigarette smoke induces cyclooxygenase 2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: Implications for lung inflammation and cancer. Am J Physiol Lung Cell Mol Physiol. 2004;287(5):L981YL991.
15. Zhao D, Xu D, Zhang X, et al. Interaction of cyclooxygenase-2 variants and smoking in pancreatic cancer: A possible role of nucleophosmin. Gastroenterol. 2009;136:1659-1668.
16. Panguluri RCK, Long LO, Chen W, et al. COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis. 2004;25(6):961-966.
17. Ding XZ, Hennig R, Adrian TE. Lipoxygenase and cyclooxygenase metabolism: New insights in treatment and chemoprevention of pancreatic cancer. Mol Cancer. 2003;2:10-21.
18. Sakoda LC, Gao YT, Chen BE, et al. Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: A population-based study in Shanghai, China. Carcinogenesis. 2006;27(6):1251-1256.
19. Shahedi K, Lindström S, Zheng SL, et al. Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer. 2006;119:668-672.
20. Gao J, Ke Q, Ma HX, et al. Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population. J Toxicol Environ Health A. 2007;70(11):908-915.
21. Moons LMG, Kuipers EJ, Rygiel AM, et al. COX-2 CA-haplotype is a risk factor for the development of esophageal adenocarcinoma. Am J Gastroenterol. 2007;102(11):2373-2379.
22. Upadhyay R, Jain M, Kumar S, et al. Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for esophageal squamous cell carcinoma. Mutat Res. 2009;663:52-59.
23. Vogel U, Christensen J, Wallin H, et al. Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res. 2008;639:89-100.
24. Ferguson HR, Wild CP, Anderson LA, et al. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2008;17(3):727-731.
25. Cheng I, Liu X, Plummer SJ, et al. COX-2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer. 2007;97:557-561.
26. Danforth KN, Hayes RB, Rodriguez C, et al. Polymorphic variants in PTGS2 and prostate cancer risk: Results from two large nested case-control studies. Carcinogenesis. 2008;29(3):568-572.
27. Kosaka T, Miyata A, Ihara H, et al. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur J Biochem. 2004;221:889-897.
28. Daly AK, Steen VM, Fairbrother KS, et al. CYP2D6 multiallelism. Methods Enzymol. 1996;272:199-210.
29. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003;73:1162-1169.
30. Warshaw AL, Fernandez-Del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992;326:455-456.
31. Lochan R, Daly AK, Reeves HL, et al. Genetic susceptibility in pancreatic ductal adenocarcinoma. Br J Surg. 2008;95:22-32.
32. Silverman DT, Dunn JA, Hoover RN, et al. Cigarette smoking and pancreas cancer: A case-control study based on direct interviews. J Natl Cancer Inst. 1994;86:1510-1516.
33. Fuchs CS, Colditz GA, Stampfer MJ, et al. A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med. 1996;156:2255-2260.
34. Xing LL, Wang ZN, Jiang L, et al. Cyclooxygenase 2 polymorphism and colorectal cancer: -765G9C variant modifies risk associated with smoking and body mass index. World J Gastroenterol. 2008;14(11):1785-1789.
35. Schuller HM, Zhang L, Weddle DL, et al. The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. J Cancer Res Clin Oncol. 2002;128:525-532.
36. Papafili A, Hill MR, Brull DJ, et al. Common promoter variant in cyclooxygenase-2 represses gene expression: Evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol. 2002;22(10):1631-1636.
37. Chan IHS, Tang NLS, Leung TF, et al. Association of prostaglandin- endoperoxide synthase 2 gene polymorphisms with asthma and atopy in Chinese children. Allergy. 2007;62:802-809.
38. Zhang Z, Sheng H, Shao J et al. Posttranscriptional regulation of cyclooxygenase-2 in rat intestinal epithelial cells. Neoplasia. 2000;2(6):523-530.
39. Campa D, Zienolddiny S, Maggini V, et al. Association of a common polymorphism in the cyclooxygenase gene with risk of non-small cell lung cancer. Carcinogenesis. 2004;25(2):229-235.
40. Hu Z, Miao X, Ma H, et al. A common polymorphism in the 3'UTR of cyclooxygenase-2 /prostaglandin synthase-2 gene and risk of lung cancer in a Chinese population. Lung Cancer. 2005;48:11-17.
41. Campa D, Hung RJ, Mates D, et al. Lack of association between polymorphisms in inflammatory genes and lung cancer risk. Cancer Epidemiol Bio Prev. 2005;14:538-539.
42. Sorensen M, Autrup H, Tjonneland A, et al. A genetic polymorphism in prostaglandin synthase-2 (8473T9C) and the risk of lung cancer. Cancer Lett. 2005;226(1):49-54.
43. Langsenlehner U, Yazdani-Biuki B, Eder T, et al. The cyclooxygenase-2 (PTGS2) 8473T9C polymorphisms associated with breast cancer risk. Clin Cancer Res. 2006;12(4):1392-1394.